By Josh Beckerman
Precigen received Food and Drug Administration approval of its lead product candidate, a drug for treatment of adults with recurrent respiratory papillomatosis.
The drug, which had been known as PRGN-2012, is now called Papzimeos.
Recurrent respiratory papillomatosis, caused by persistent human papillomavirus infection, leads to the growth of benign tumors in the respiratory tract, generally in the larynx.
In February, the FDA granted priority review, with a Prescription Drug User Fee Act target action date of Aug. 27.
Write to Josh Beckerman at josh.beckerman@wsj.com
(END) Dow Jones Newswires
August 14, 2025 19:21 ET (23:21 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.